Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Pfizer    PFE

PFIZER (PFE)
Mes dernières consult.
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets

Pfizer : UK gives Pfizer world's first over-the-counter Viagra approval

share with twitter share with LinkedIn share with facebook
share via e-mail
0
11/28/2017 | 05:04pm CEST
The Pfizer logo is seen at their world headquarters in Manhattan, New York, U.S.

LONDON (Reuters) - Pfizer's big-selling erectile dysfunction drug Viagra has been given a green light for sale without a prescription in Britain, the first country to grant it over-the-counter status.

The U.S. drugmaker said on Tuesday it was working on plans to launch the non-prescription version of the medicine, known as Viagra Connect, in the United Kingdom in the spring of 2018.

The drug will only be available in pharmacies and its supply will depend on pharmacists' assessment of its suitability for each individual.

Viagra has been one of the pharmaceutical industry's most successful prescription products since its launch in 1998, following a serendipitous discovery of its effects by researchers who had been studying it as a heart medicine.

It achieved peak worldwide sales of more than $2 billion in 2012 but sales have since declined as patents have expired, prompting Pfizer to explore extending its brand value as a non-prescription drug.

Viagra is so far the only erectile dysfunction medicine to be reclassified from "prescription only medicine" to "pharmacy" status in Britain. The change follows a lengthy review by the Medicines and Healthcare products Regulatory Agency (MHRA).

Pfizer will continue to make Viagra available as a prescription drug but the option of also buying it over-the-counter is likely to reduce demand for potentially ineffective and dangerous fakes.

"It's important men feel they have fast access to quality and legitimate care, and do not feel they need to turn to counterfeit online supplies which could have potentially serious side effects," said Mick Foy, the MHRA's group manager in vigilance and risk management of medicines.

(Reporting by Ben Hirschler; Editing by Alexander Smith and Mark Potter)

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on PFIZER
04:49aPFIZER : Trademark Application for "RIXZURE" Filed
AQ
07/19PFIZER : Trademark Application for "COUNT ON YOUR BABY'S CHECKUPS, BECAUSE BABY ..
AQ
07/19PFIZER : An Application for the Trademark "COUNT ON BABY CHECKUPS, BECAUSE BABY ..
AQ
07/19PFIZER : Leaders from Pfizer, Sanofi, Eli Lilly and Applied Informatics to Speak..
AQ
07/19PFIZER : Findings from Pfizer Yields New Findings on Enterobacteriaceae (In Vitr..
AQ
07/19MERCK AND : to Limit Drug-Price Increases, Cut Some Prices
DJ
07/19MERCK : Vyriad Announces Collaboration with Merck KGaA, Darmstadt, Germany, and ..
AQ
07/19Pfizer's tanezumab meets in Phase III for OA pain
AQ
07/19PFIZER : Novartis joins Pfizer in deferring drug-price hikes
AQ
07/18Novartis hints at 2018 outlook hike despite drug price freeze
RE
More news
News from SeekingAlpha
07/19My Dividend Growth Portfolio - Q2 2018 Summary 
07/19Jane's June Dividend Increases And Income - Retirement Accounts 
07/19Liquidia Technologies Readies $50 Million IPO 
07/19Big Pharma in the red on ramped up pressure on drug prices 
07/19YOUR DAILY PHARMA SCOOP : Tonix Progresses, J&J Succeeds, Quidel Is Cleared 
Financials ($)
Sales 2018 54 297 M
EBIT 2018 20 784 M
Net income 2018 13 077 M
Debt 2018 21 973 M
Yield 2018 3,65%
P/E ratio 2018 17,19
P/E ratio 2019 15,62
EV / Sales 2018 4,46x
EV / Sales 2019 4,26x
Capitalization 220 B
Chart PFIZER
Duration : Period :
Pfizer Technical Analysis Chart | PFE | US7170811035 | 4-Traders
Technical analysis trends PFIZER
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 21
Average target price 39,8 $
Spread / Average Target 6,5%
EPS Revisions
Managers
NameTitle
Ian C. Read Chairman & Chief Executive Officer
Albert Bourla Chief Operating Officer & Director
Frank A. D'Amelio Chief Financial Officer & EVP-Business Operations
Freda C. Lewis-Hall Chief Medical Officer & Executive Vice President
W. Don Cornwell Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
PFIZER3.98%220 236
JOHNSON & JOHNSON-7.59%346 292
ROCHE HOLDING LTD.-4.77%200 995
NOVARTIS-2.11%200 139
MERCK AND COMPANY11.85%168 225
AMGEN10.87%128 318